Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.8286
Nov 16 • 3:59 PM ET Dollar change-0.0414 Percentage change(-4.76%)
Aftermarket Close
0.8090
Aftermarket • 4:43 PM ET Dollar change-0.0196 Percentage change(-2.37%)
Index
-
Market Cap
13.82M
Enterprise Value
1.90M
Income
-8.71M
Sales
2.34M
Book/sh
0.73
Cash/sh
0.71
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
5
IPO
Jan 05, 1998
P/E
-
Forward P/E
-
PEG
-
P/S
5.91
P/B
1.14
P/C
1.16
P/FCF
-
EV/EBITDA
-
EV/Sales
0.81
Quick Ratio
6.03
Current Ratio
6.03
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-0.48
EPS next Y
-0.88
EPS next Q
-0.12
EPS this Y
24.89%
EPS next Y
-47.75%
EPS next 5Y
-
EPS past 3/5Y
39.48% 33.49%
Sales past 3/5Y
0.31% 50.02%
EPS Y/Y TTM
64.88%
Sales Y/Y TTM
-56.64%
EPS Q/Q
67.12%
Sales Q/Q
-100.00%
Insider Own
19.03%
Insider Trans
0.00%
Inst Own
10.53%
Inst Trans
-0.02%
ROA
-59.33%
ROE
-76.87%
ROIC
-71.57%
Gross Margin
-
Oper. Margin
-458.56%
Profit Margin
-372.69%
SMA20
-14.31%
SMA50
-20.98%
SMA200
-37.07%
Trades
Shs Outstand
16.67M
Shs Float
13.50M
52W High
2.46 -66.32%
52W Low
0.87 -4.76%
Volatility
9.66% 11.94%
ATR (14)
0.10
RSI (14)
38.39
Beta
1.63
Rel Volume
1.14
Avg Volume
118.58K
Volume
135,584
Perf Week
-16.34%
Perf Month
-20.33%
Perf Quarter
-27.95%
Perf Half Y
-40.39%
Perf YTD
-44.39%
Perf Year
-10.23%
Perf 3Y
-69.98%
Perf 5Y
-94.04%
Perf 10Y
-98.22%
Prev Close
0.87
Price
0.83
Change %
-4.76%
Consensus
Strong Buy
Avg. Price Target
$7.87
Implied Upside
+849.8%
Analysts6incl. previous ratings
Rating Distribution6 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Mar 05, 2025Initiated
CCanaccord Genuity
Buy$8+865.5%
Mar 25, 2021Initiated
PPiper Sandler
Overweight$6+624.1%
Mar 19, 2021Initiated
CCantor Fitzgerald
Overweight$6+624.1%
May 12, 2020Downgrade
PPiper Sandler
Overweight → Neutral$5 → $2.50+201.7%
May 30, 2019Initiated
RROTH Capital
Buy
Mar 01, 2019Initiated
JJanney
Buy
Dec 03, 2018Upgrade
PPiper Jaffray
Neutral → Overweight
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
Co-FounderDr. Juan F. Vera M.D.
Director of AdministrationMs. Elizabeth Donnelly
Director of Corporate Operations & External CommunicationsDr. Maria-Bernadette Madel Ph.D.
Vice President of Human ResourcesMr. Edmund Cheung
Head of Clinical OperationsPatricia Allison